FIGURE 4.

Key histological and laboratory findings among patients with nonrejection biopsy and increased dd-cfDNA results. A, Box plots show the median eGFR and interquartile range among 333 patients with a nonrejection biopsy, stratified by the number of dd-cfDNA tests with an increased result (≥1%): 0 (n = 277), 1 (n = 38), or 2 or more (n = 18). Wilcoxon rank-sum test with FDR correction for multiple testing was used to compare eGFR among patients with 0 and 1 increased dd-cfDNA test result (P = 0.0006) or patients with 2 increased dd-cfDNA test results (P = 0.00018), ***P < 0.001. B, Key histological and laboratory findings among patients with 1 (n = 38) and ≥2 (n = 18) increased (≥1%) dd-cfDNA results. High immune risk category includes patients with at least one of the following: de novo DSA, retransplant, C4d positivity; recurrent disease category includes IgA nephropathy and lupus glomerulonephritis; infection category includes pyelonephritis, urinary tract infection, parvovirus, CMV and EBV. Suspected ABMR was noted as such on the histology report by the pathologist. ABMR, antibody-mediated rejection; dd-cfDNA, donor-derived cell-free DNA; EBV, Epstein-Barr virus; eGFR, estimated glomerular filtration rate; FDR, false discovery rate; TCMR, T cell–mediated rejection.